Literature DB >> 12370212

Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans.

Bodo E Strauer1, Michael Brehm, Tobias Zeus, Matthias Köstering, Anna Hernandez, Rüdiger V Sorg, Gesine Kögler, Peter Wernet.   

Abstract

BACKGROUND: Experimental data suggest that bone marrow-derived cells may contribute to the healing of myocardial infarction (MI). For this reason, we analyzed 10 patients who were treated by intracoronary transplantation of autologous, mononuclear bone marrow cells (BMCs) in addition to standard therapy after MI. METHODS AND
RESULTS: After standard therapy for acute MI, 10 patients were transplanted with autologous mononuclear BMCs via a balloon catheter placed into the infarct-related artery during balloon dilatation (percutaneous transluminal coronary angioplasty). Another 10 patients with acute MI were treated by standard therapy alone. After 3 months of follow-up, the infarct region (determined by left ventriculography) had decreased significantly within the cell therapy group (from 30+/-13 to 12+/-7%, P=0.005) and was also significantly smaller compared with the standard therapy group (P=0.04). Likewise, infarction wall movement velocity increased significantly only in the cell therapy group (from 2.0+/-1.1 to 4.0+/-2.6 cm/s, P=0.028). Further cardiac examinations (dobutamine stress echocardiography, radionuclide ventriculography, and catheterization of the right heart) were performed for the cell therapy group and showed significant improvement in stroke volume index, left ventricular end-systolic volume and contractility (ratio of systolic pressure and end-systolic volume), and myocardial perfusion of the infarct region.
CONCLUSIONS: These results demonstrate for the first time that selective intracoronary transplantation of autologous, mononuclear BMCs is safe and seems to be effective under clinical conditions. The marked therapeutic effect may be attributed to BMC-associated myocardial regeneration and neovascularization.

Entities:  

Mesh:

Year:  2002        PMID: 12370212     DOI: 10.1161/01.cir.0000034046.87607.1c

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  400 in total

1.  Bone marrow-derived stem cells for ischemic hearts.

Authors:  Alfred A Kocher
Journal:  Wien Klin Wochenschr       Date:  2003-02-28       Impact factor: 1.704

Review 2.  CD34-positive stem cells: in the treatment of heart and vascular disease in human beings.

Authors:  Alexander R Mackie; Douglas W Losordo
Journal:  Tex Heart Inst J       Date:  2011

3.  The combination of angiotensin II and 5-azacytidine promotes cardiomyocyte differentiation of rat bone marrow mesenchymal stem cells.

Authors:  YuJie Xing; AnLin Lv; Li Wang; XueBo Yan
Journal:  Mol Cell Biochem       Date:  2011-09-21       Impact factor: 3.396

4.  An emerging cell-based strategy in orthopaedics: endothelial progenitor cells.

Authors:  Kivanc Atesok; Tomoyuki Matsumoto; Jon Karlsson; Takayuki Asahara; Anthony Atala; M Nedim Doral; Rene Verdonk; Ru Li; Emil Schemitsch
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2012-03-09       Impact factor: 4.342

Review 5.  Recipes for adult stem cell plasticity: fusion cuisine or readymade?

Authors:  M R Alison; R Poulsom; W R Otto; P Vig; M Brittan; N C Direkze; M Lovell; T C Fang; S L Preston; N A Wright
Journal:  J Clin Pathol       Date:  2004-02       Impact factor: 3.411

6.  Human mesenchymal stem cells make cardiac connexins and form functional gap junctions.

Authors:  Virginijus Valiunas; Sergey Doronin; Laima Valiuniene; Irina Potapova; Joan Zuckerman; Benjamin Walcott; Richard B Robinson; Michael R Rosen; Peter R Brink; Ira S Cohen
Journal:  J Physiol       Date:  2004-02-06       Impact factor: 5.182

Review 7.  Autologous stem cells for functional myocardial repair.

Authors:  Yitzhack Schwartz; Ran Kornowski
Journal:  Heart Fail Rev       Date:  2003-07       Impact factor: 4.214

8.  Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction.

Authors:  Hidemasa Oh; Steven B Bradfute; Teresa D Gallardo; Teruya Nakamura; Vinciane Gaussin; Yuji Mishina; Jennifer Pocius; Lloyd H Michael; Richard R Behringer; Daniel J Garry; Mark L Entman; Michael D Schneider
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-06       Impact factor: 11.205

9.  Overexpression of FABP3 inhibits human bone marrow derived mesenchymal stem cell proliferation but enhances their survival in hypoxia.

Authors:  Suna Wang; Yifu Zhou; Oleg Andreyev; Robert F Hoyt; Avneesh Singh; Timothy Hunt; Keith A Horvath
Journal:  Exp Cell Res       Date:  2014-02-27       Impact factor: 3.905

Review 10.  Renal repair: role of bone marrow stem cells.

Authors:  Fangming Lin
Journal:  Pediatr Nephrol       Date:  2008-06       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.